A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD
A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD
To determine if ABX-IL8 will improve shortness of breath.
Chronic Obstructive Pulmonary Disease (COPD) is defined as a disease state characterized by
 the presence of airflow obstruction due to chronic bronchitis or emphysema. The airflow
 obstruction is generally progressive, may be accompanied by airway hyper-reactivity, and may
 be partially reversible. Inflammation in the lungs is triggered by exposure to inhaled toxic
 substances that can lead to tissue damage, mucous secretion, airways narrowing and tissue
 destruction.

 Interleukin-8 (IL-8) plays a major role in elevating sputum in patients with COPD and may
 contribute to tissue destruction. Therefore, the highly specific antibody to IL-8 (such as
 ABX-IL8) may help to reduce mucous production and tissue destruction.
Inclusion Criteria:

 -  > 50 years old

 -  > 20 pack-year of smoking

 -  Diagnosed with COPD and chronic bronchitis

 Exclusion Criteria:

 -  Patients with bronchiectasis, cystic fibrosis, tuberculosis, asthma, alpha-1
 antitrypsin deficiency, CHF

 -  Require oxygen therapy

 -  Uncontrolled hypertension

 -  HIV or Hepatitis

 -  Recent history of COPD exacerbation

 -  Patients with cancer

 -  Recent history of infection